

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		09664444	
	Filing Date		2000-09-18	
	First Named Inventor	John C. Bell		
	Art Unit	1645		
	Examiner Name	R. Zeman		
	Attorney Docket Number	18003		

U.S.PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

Add

NON-PATENT LITERATURE DOCUMENTS				Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	09664444
Filing Date	2000-09-18
First Named Inventor	John C. Bell
Art Unit	1645
Examiner Name	R. Zeman
Attorney Docket Number	18003

1	Ahmed, et al., "Ability of the Matrix Protein of Vesicular Stomatitis Virus to Suppress Beta Interferon Gene Expression is Genetically Correlated with the Inhibition of Host RNA and Protein Synthesis", Journal of Virology, Vol. 77, No. 8, 2003, 4646-4657.	<input type="checkbox"/>
2	Coukos, et al., "Use of Carrier Cells to Deliver a Replication-Selective Herpes Simplex Virus-1 Mutant for the Intraperitoneal Therapy of Epithelial Ovarian Cancer", Clinical Cancer Research, Vol. 5, June 1999, pages 1523-1537.	<input type="checkbox"/>
3	Desforges, et al. "Different Host-Cell Shutoff Strategies Related to the Matrix Protein lead to Persistence of Vesicular Stomatitis Virus Mutants on Fibroblast Cells", Virus Res., 76(1), July 2001, pages 87-102. (Abstract)	<input type="checkbox"/>
4	Ferran, et al., "The Vesicular Stomatitis Virus Matrix Protein Inhibits Transcription from the Human Beta Interferon Promoter", Journal of Virology, Vol. 71, No. 1, 1997, pages 371-377.	<input type="checkbox"/>
5	Marcus, et al., "Interferon Induction by Viruses. III. Vesicular Stomatitis Virus: Interferon-Inducing Particle Activity Requires Partial Transcription of Gene N", J. Gen. Virol., 47(1), 1980, pages 89-96. (Abstract)	<input type="checkbox"/>
6	Pasternak, et al., "Stress-Induced Increase of Hexose Transport as a Novel Index of Cytopathic Effects in Virus-Infected Cells: Role of the L Protein in the Action of Vesicular Stomatitis Virus", Virology, 166(2), 1988, pages 379-386. (Abstract)	<input type="checkbox"/>
7	Stanners, et al., "Analysis of VSV Mutant with Attenuated Cytopathogenicity: Mutation in Viral Function, P, for Inhibition of Protein Synthesis", Cell, 11(2), 1977, pages 273-281. (Abstract)	<input type="checkbox"/>
8	Winship, et al., "Distinctive Characteristics of Crude Interferon from Virus-Infected Guinea-Pig Embryo Fibroblasts", Journal of General Virology, Vol. 65, 1984, pages 843-847. (Abstract)	<input type="checkbox"/>
9	Current Office Action (3/27/2008) and Pending claims (filed 1/7/08) for U.S. Patent Application No. 10/743,649	<input type="checkbox"/>
10	Pending claims (filed 1/17/08) for U.S. Patent Application No. 11685483	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

Add

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	09664444	
Filing Date	2000-09-18	
First Named Inventor	John C. Bell	
Art Unit	1645	
Examiner Name	R. Zeman	
Attorney Docket Number	18003	

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.